Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.08 USD
−12.85 M USD
0.00 USD
6.25 M
About Grace Therapeutics, Inc.
Sector
CEO
Prashant Kohli
Headquarters
Princeton
Website
Founded
2002
FIGI
BBG001NMDXS6
Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GRCE is 3.82 USD — it has decreased by −2.71% in the past 24 hours. Watch Grace Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Grace Therapeutics, Inc. stocks are traded under the ticker GRCE.
GRCE stock has risen by 2.07% compared to the previous week, the month change is a 31.23% rise, over the last year Grace Therapeutics, Inc. has showed a 72.07% increase.
We've gathered analysts' opinions on Grace Therapeutics, Inc. future price: according to them, GRCE price has a max estimate of 12.50 USD and a min estimate of 8.00 USD. Watch GRCE chart and read a more detailed Grace Therapeutics, Inc. stock forecast: see what analysts think of Grace Therapeutics, Inc. and suggest that you do with its stocks.
GRCE reached its all-time high on Jul 24, 2013 with the price of 967,680.00 USD, and its all-time low was 1.72 USD and was reached on Sep 22, 2023. View more price dynamics on GRCE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GRCE stock is 9.16% volatile and has beta coefficient of 1.01. Track Grace Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Grace Therapeutics, Inc. there?
Today Grace Therapeutics, Inc. has the market capitalization of 41.17 M, it has decreased by −2.76% over the last week.
Yes, you can track Grace Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Grace Therapeutics, Inc. is going to release the next earnings report on Feb 17, 2025. Keep track of upcoming events with our Earnings Calendar.
GRCE earnings for the last quarter are −0.30 USD per share, whereas the estimation was −0.37 USD resulting in a 18.92% surprise. The estimated earnings for the next quarter are −0.32 USD per share. See more details about Grace Therapeutics, Inc. earnings.
Grace Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
GRCE net income for the last quarter is −3.43 M USD, while the quarter before that showed −2.62 M USD of net income which accounts for −31.14% change. Track more Grace Therapeutics, Inc. financial stats to get the full picture.
No, GRCE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 4.00 employees. See our rating of the largest employees — is Grace Therapeutics, Inc. on this list?
Like other stocks, GRCE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Grace Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Grace Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Grace Therapeutics, Inc. stock shows the sell signal. See more of Grace Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.